- Home
- KLRS vs MOBX Comparison
KLRS vs MOBX Comparison
Compare KLRS & MOBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- MOBX
- Stock Information
- Founded
- KLRS 2019
- MOBX 2020
- Country
- KLRS United States
- MOBX United States
- Employees
- KLRS N/A
- MOBX N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- MOBX
- Sector
- KLRS Health Care
- MOBX
- Exchange
- KLRS Nasdaq
- MOBX Nasdaq
- Market Cap
- KLRS 46.0M
- MOBX 52.0M
- IPO Year
- KLRS N/A
- MOBX N/A
- Fundamental
- Price
- KLRS $4.97
- MOBX $0.69
- Analyst Decision
- KLRS Strong Buy
- MOBX
- Analyst Count
- KLRS 2
- MOBX 0
- Target Price
- KLRS $23.00
- MOBX N/A
- AVG Volume (30 Days)
- KLRS 175.7K
- MOBX 2.3M
- Earning Date
- KLRS 11-15-2025
- MOBX 12-18-2025
- Dividend Yield
- KLRS N/A
- MOBX N/A
- EPS Growth
- KLRS N/A
- MOBX N/A
- EPS
- KLRS N/A
- MOBX N/A
- Revenue
- KLRS N/A
- MOBX $10,984,000.00
- Revenue This Year
- KLRS N/A
- MOBX N/A
- Revenue Next Year
- KLRS N/A
- MOBX N/A
- P/E Ratio
- KLRS N/A
- MOBX N/A
- Revenue Growth
- KLRS N/A
- MOBX 180.13
- 52 Week Low
- KLRS $2.14
- MOBX $0.55
- 52 Week High
- KLRS $24.15
- MOBX $2.47
- Technical
- Relative Strength Index (RSI)
- KLRS 49.92
- MOBX 38.66
- Support Level
- KLRS $4.70
- MOBX $0.65
- Resistance Level
- KLRS $5.30
- MOBX $0.75
- Average True Range (ATR)
- KLRS 0.41
- MOBX 0.07
- MACD
- KLRS -0.06
- MOBX -0.01
- Stochastic Oscillator
- KLRS 67.48
- MOBX 18.07
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.